Covidien to Highlight Technetium-99m Development at SNM

 

June 12, 2009

June 12, 2009 - Covidien will be highlighting at the 2009 SNM Annual Conference in Toronto, June 13-17, its abbreviated new drug application (ANDA) for its kit for the preparation of technetium-99m (Tc-99m) sestamibi injection and radiosotope development.

Covidien's generic product is pharmaceutically equivalent to Cardiolite1, a myocardial perfusion imaging agent used for detecting coronary artery disease. With FDA approval of the ANDA, which was filed by the company's Mallinckrodt subsidiary, Covidien's generic product is now available for customers in the United States.

Covidien's will also focus on its co-marketing agreement with Siemens' PETNET to offer high and low energy radioisotopes to nuclear medicine sites. Through the agreement, Coviden Imaging Solutions and PETNET created a network of nuclear imaging product offerings to expand customer access to a wider range of products, including molecular imaging agents, or radioisotopes, designed to illuminate conditions such as cancer or heart disease when doing SPECT and PET scans.

It will also underscore its agreement with Bacock & Wilcox Technical Services Group Inc. to develop technology for the manufacture of molybdenum-99 (Mo-99), the parent isotope of Tc-99m, the most widely used radioisotope for molecular imaging and nuclear medicine procedures. This collaboration is an initial step toward establishing a large-scale U.S. supply of medical isotopes.

For more information: www.covidien.com